Press Releases

CHICAGO, Ill. and ATLANTA, Ga., June 3, 2024 (SEND2PRESS NEWSWIRE)  Financial mogul-turned-producer, Michelle Renee, is making waves in the entertainment industry with the recent launch of the innovative reality show, “First Ladies of The Crypto Cartel,” a groundbreaking series spotlighting five stylish, tech-savvy women based in Chicago and Atlanta as they build digital dynasties. Produced by Money Gossip Productions, the streaming show combines the expected... (continue reading...)

All 17 Alliance College-Ready Public High Schools Achieve National Recognition, Competing with Top U.S. Charter, Magnet, and STEM Schools

LOS ANGELES, June 3, 2024 /PRNewswire/ -- Alliance College-Ready Public Schools proudly announces its recognition by the U.S. News & World Report as operating some of the nation's top public high schools. This prestigious distinction reflects an exhaustive evaluation of nearly 25,000 public schools across 50 states and the District... (continue reading...)

Expands WM’s Comprehensive Environmental Solutions in the Growing Healthcare Market While Advancing WM’s Sustainability Commitments

• Provides a complementary business platform in the healthcare market, a sector with attractive near- and long-term growth dynamics
• Positions WM to offer customers the opportunity to partner with a single service provider with a comprehensive suite of environmental solutions
• Builds on WM’s sustainability commitments to help... (continue reading...)

Surveillance Monitoring with Both AlloSure Kidney and the AlloView AI-Enabled Risk Prediction Model Improves the Detection of All Types of Allograft Rejection

AlloSure Kidney Detected Subclinical Rejection in Clinically Stable Patients and AlloSure Kidney dd-cfDNA Levels were Elevated Prior to Biopsy Proven Rejection in an Analysis of Patients Receiving Consecutive Biopsies

AlloSure dd-cfDNA Levels Declined in Response to Immunosuppression Treatment Suggesting... (continue reading...)

~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~

~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington’s disease ~

~ Receiving RMAT designation enables increased collaboration with the FDA on regulatory approval planning, in addition to the opportunity for expedited product development ~

LEXINGTON, Mass. and AMSTERDAM, June 03, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:... (continue reading...)